Inventor · disambiguated record
Min Ding
Also filed as: DING MIN · DING MIN-PEY
40 granted patents·17 pending applications·398 citations·filing 1999–2024
97Inventor score
Top patents by PatentIndex Score
57 records- 0198US7153848B2Inhibitors of HCV replicationBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Dec 26, 2006·90 cites·32 claims
- 0297US7348425B2Inhibitors of HCV replicationBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Mar 25, 2008·59 cites·1 claims
- 0395US9850225B2Compounds useful as immunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Dec 26, 2017·13 cites·15 claims
- 0495US7521443B2Cyclopropyl fused indolobenzazepine HCV NS5B inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Apr 21, 2009·13 cites·5 claims
- 0595US7452876B2Cyclopropyl fused indolobenzazepine HCV NS5B inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Nov 18, 2008·21 cites·14 claims
- 0693US7485633B2Cyclopropyl fused indolobenzazepine HCV NS5B inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Feb 3, 2009·20 cites·3 claims
- 0792US7456166B2Cyclopropyl fused indolobenzazepine HCV NS5B inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Nov 25, 2008·24 cites·17 claims
- 0892US7399758B2Cyclopropyl fused indolobenzazepine HCV NS5B inhibitorsMEANWELL NICHOLAS A·Filed 2006·Granted Jul 15, 2008·28 cites·13 claims
- 0991US7521442B2Cyclopropyl fused indolobenzazepine HCV NS5B inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Apr 21, 2009·18 cites·12 claims
- 1091US7521441B2Cyclopropyl fused indolobenzazepine HCV NS5B inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Apr 21, 2009·18 cites·12 claims
- 1189US9295687B1Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the sameMEDICINES CO·Filed 2015·Granted Mar 29, 2016·9 cites·30 claims
- 1289US7538102B2Compounds for the treatment of Hepatitis CBRISTOL MYERS SQUIBB CO·Filed 2008·Granted May 26, 2009·16 cites·13 claims
- 1388US10669272B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 2, 2020·4 cites·13 claims
- 1488US7541351B2Compounds for the treatment of hepatitis CBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Jun 2, 2009·11 cites·11 claims
- 1587US7541353B2Compounds for the treatment of hepatitis CBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Jun 2, 2009·11 cites·12 claims
- 1686US2025213540A1Pharmaceutical compositions and methods for producing low impurity concentrations of the sameCHIESI FARM SPA·Filed 2024·Application pending·0 cites
- 1785US11866430B2Naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jan 9, 2024·3 cites·11 claims
- 1885US7547690B2Compounds for the treatment of Hepatitis CBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Jun 16, 2009·8 cites·13 claims
- 1983US9439921B2Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the sameTHE MEDICINES CO·Filed 2016·Granted Sep 13, 2016·4 cites·26 claims
- 2082US9700575B2Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the sameCHIESI FARM SPA·Filed 2016·Granted Jul 11, 2017·3 cites·26 claims
- 2182US8383094B2Hepatitis C virus inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Feb 26, 2013·3 cites·18 claims
- 2280US2023302002A1Pharmaceutical Compositions and Methods for Stabilizing the SameCHISEI FARM S P A·Filed 2023·Application pending·0 cites
- 2379US10039780B2Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the sameCHIESI FARM SPA·Filed 2017·Granted Aug 7, 2018·2 cites·23 claims
- 2478US8133884B2Compounds for the treatment of hepatitis CMARTIN SCOTT W·Filed 2009·Granted Mar 13, 2012·5 cites·13 claims
- 2574US7169803B2N-substituted prodrugs of fluorooxindolesBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Jan 30, 2007·1 cites·10 claims
- 2671US2022000849A1Pharmaceutical compositions and methods for producing low impurity concentrations of the sameCHIESI FARM SPA·Filed 2021·Application pending·0 cites
- 2770US11058672B2Pharmaceutical compositions and methods for producing low impurity concentrations of the sameCHIESI FARM SPA·Filed 2018·Granted Jul 13, 2021·0 cites·11 claims
- 2870US2009162318A1Cyclopropyl Fused Indolobenzazepine HCV NS5B InhibitorsBRISTOL MYERS SQUIBB CO·Filed 2009·Application pending·0 cites
- 2969US9738642B2Triazolopyridine ether derivatives and their use in neurological and pyschiatric disordersBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Aug 22, 2017·1 cites·11 claims
- 3068US10864249B2High purity oritavancin and method of producing sameMELINTA THERAPEUTICS INC·Filed 2019·Granted Dec 15, 2020·0 cites·21 claims
- 3168US2013171098A1Cyclopropyl Fused Indolobenzazepine HCV NS5B InhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 3267US11713316B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Aug 1, 2023·0 cites·11 claims
- 3367US2014045816A1Cyclopropyl Fused Indolobenzazepine HCV NS5B InhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 3465US2010105743A1Pharmaceutical compositions and methods for stabilizing the sameKRISHNA GOPAL·Filed 2009·Application pending·0 cites
- 3564US2014186299A1Cyclopropyl Fused Indolobenzazepine HCV NS5B InhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 3661US10954238B1Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Mar 23, 2021·0 cites·11 claims
- 3761US2011311480A1Cyclopropyl Fused Indolobenzazepine HCV NS5B InhibitorsBENDER JOHN A·Filed 2011·Application pending·0 cites
- 3861US2019117660A1Pharmaceutical Compositions and Methods for Stabilizing the SameCHIESI FARM SPA·Filed 2018·Application pending·0 cites
- 3959US2010113534A1Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The SameMOTHERAM RAJESHWAR·Filed 2009·Application pending·0 cites
- 4057US2014005233A1Pharmaceutical compositions and methods for producing low impurity concentrations of the sameMEDICINES CO·Filed 2013·Application pending·0 cites
- 4156US12234481B2Use of exosome derived from decidual natural killer (dNK) cells or dNK cell subset in preparation of drug and auxiliary therapeutic agent for infertility-related diseasesPHARCHOICE THERAPEUTICS INC·Filed 2020·Granted Feb 25, 2025·0 cites·10 claims
- 4256US2012322836A1Pharmaceutical compositions and methods for stabilizing the sameKRISHNA GOPAL·Filed 2012·Application pending·0 cites
- 4355US7601686B2Hepatitis C virus inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Oct 13, 2009·0 cites·23 claims
- 4455US6034113ADerivatives of 1,3,4-oxadiazoloneBRISTOL MYERS SQUIBB CO·Filed 1999·Granted Mar 7, 2000·11 cites·16 claims
- 4554US11964973B2Substituted bicyclic compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Apr 23, 2024·0 cites·11 claims
- 4654US2023061608A1Substituted quinolinonyl piperazine compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 4752US10328118B2High purity oritavancin and method of producing sameTHE MEDICINES CO·Filed 2017·Granted Jun 25, 2019·0 cites·10 claims
- 4851US2022275048A1Dimer immunoadhesin, pharmaceutical compostion and use thereofPHARCHOICE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4951US2023089255A1Combinations of dgk inhibitors and checkpoint antagonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 5050US9649352B2High purity oritavancin and method of producing sameTHE MEDICINES CO·Filed 2015·Granted May 16, 2017·0 cites·15 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Min Ding files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →